
Nikhil Waingankar, MD Email Nikhil Waingankar

-
- Position
- ASSISTANT PROFESSOR | Urology
-
- Specialty
- Urology
-
- Language
- English
-
- Hospital Affiliation
- Mount Sinai Queens
-
- Phone
- Mount Sinai Doctors 718-808-7777 718-808-7777
- 718-520-6100 718-520-6100
Nikhil Waingankar, MD, is an Assistant Professor of Urologic Oncology in the Department of Urology at the Icahn School of Medicine at Mount Sinai and an Attending Physician in the Department of Urology at Mount Sinai Queens. He specializes in urologic oncology and his expertise includes open, laparoscopic, endoscopic, and robotic surgical techniques. His clinical focus includes treating patients with cancers of the prostate, bladder, kidney, and testis. He also cares for patients with benign urologic conditions such as benign prostatic hyperplasia, kidney stones, and urinary tract infections.
Dr. Waingankar received his medical degree from the University of Oklahoma College of Medicine. After finishing his internship in general surgery at Johns Hopkins, he completed a residency in urology at North Shore – Long Island Jewish Health System where he received academic awards and served as Chief Resident. He subsequently completed a fellowship in urologic oncology at the esteemed Fox Chase Cancer Center in Philadelphia. During the fellowship, Dr. Waingankar completed advanced urologic surgery training and conducted research in health services, which encompassed the intersection of clinical medicine with the economic, political, and public health aspects of care delivery. Specifically, he studied the roles that surgical volume, regionalization of care, and treatment delays play on outcomes for patients who undergo radical surgery for bladder cancer. In addition, he participated in the Masters of Science Program in Health Policy at the University of Pennsylvania, in which he examined physician practice patterns and adherence to guideline-based care for radical cystectomy, along with the impact this has on disparity in access to care and survival outcomes.
Dr. Waingankar provides caring and customized treatment to patients with a range of urologic cancers. He offers patients the latest advances in surgical treatment and works closely with his colleagues in medical oncology, radiation oncology, family practice, and internal medicine to provide an integrated approach to patient care with the goal of optimizing outcomes and patient experience. He finds the positive impact he has on his patients’ lives very rewarding. In addition to his clinical interests, Dr. Waingankar is involved in research at the Institute for Healthcare Delivery Science within the Mount Sinai Department of Population Health Science and Policy. His research team aims to examine the impacts of care intensity and variations in practice patterns on patient outcomes both at the national level and within the Mount Sinai Health System. He has authored several publications and book chapters and has given numerous presentations at national meetings. He is a member of the American Urological Association and the Society of Urologic Oncology.
Follow him on Twitter: https://twitter.com/nwaingankar
Certification
American Board of Urology
Clinical Focus
- Adrenalectomy
- Adrenocortical Carcinoma
- Benign Prostatic Hyperplasia
- Bladder Cancer
- Bladder Stone
- Cystoscopy
- Elevated PSA
- Evaluation of Kidney Mass
- Hydronephrosis
- Kidney Cancer
- Kidney Stones
- Nephrectomy
- Penile Cancer
- Prostate Biopsy
- Prostate Cancer
- Prostate Cancer Screening
- Prostate Laser Procedures
- Prostate-Specific Antigen (PSA) Test
- Prostatectomy
- Pyeloplasty
- Radical Cystectomy
- Robotic Kidney Surgery
- Robotic Prostate Surgery
- Testicular Cancer
- Ureteroscopy
- Urology Second Opinion
Education
MD, University of Oklahoma Health Science Center
Internship, General Surgery
Johns Hopkins Hospital
Residency, Urology
North Shore-Long Island Jewish Health System
Fellowship, Urology Oncology
Fox Chase Cancer Center
Language
English
Cancer
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Waingankar during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Astellas Pharma Inc.
- Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.